Palliative Treatment of Unresectable Bile Duct Tumours Palliative Behandlung von inoperablen Gallengangstumoren

Ramona Mayer, Heidi Stranzl, Ulrike Prettenhofer, F. Quehenberger, G. Stücklschweiger, P. Winkler , A. Hackl
{"title":"Palliative Treatment of Unresectable Bile Duct Tumours\n Palliative Behandlung von inoperablen Gallengangstumoren","authors":"Ramona Mayer,&nbsp;Heidi Stranzl,&nbsp;Ulrike Prettenhofer,&nbsp;F. Quehenberger,&nbsp;G. Stücklschweiger,&nbsp;P. Winkler ,&nbsp;A. Hackl","doi":"10.1046/j.1563-2571.2003.02049.x","DOIUrl":null,"url":null,"abstract":"<p><b>Summary:</b> <span>Purpose</span>\n : Report on outcome of intraluminal high-dose-rate iridium-192 (HDR-Ir\n <sup>192</sup>\n ) brachytherapy with or without external radiotherapy in patients with unresectable bile duct tumours suffering from symptoms of malignant obstructive jaundice. \n <span>Material and methods</span>\n : Fourteen patients (mean age: 63 years) who were unsuitable for surgical resection on preoperative evaluation/laparotomy or inoperable due to poor general condition were referred for palliative radiotherapy. After percutaneous transhepatic drainage, HDR-Ir\n <sup>192</sup>\n brachytherapy was performed with a single dose of 2.5 Gy. Brachytherapy was given twice a day with at least a 6-h interval for 2 days, 2 or 3 days apart, up to a total dose of 10 Gy. Five patients received small-volume external radiotherapy (RT) (45 – 50.4 Gy/1.8 Gy) additionally. \n <span>Results</span>\n : Palliation with relief of the aggravating symptoms of obstructive jaundice was achieved in all patients. The actuarial 2-year survival rate of all patients was 11.9 % with a median survival of 6.5 months. Patients treated with brachytherapy alone had a median survival of 4.5 months as compared with 6.5 months after combined internal and external irradiation (log rank, \n <i>P</i>\n = 0.95). \n <span>Conclusion</span> : Patients with advanced unresectable bile duct cancer face a dismal prognosis; however, biliary drainage, and intraluminal brachytherapy with or without external RT, seem to be able to improve quality of life in the remaining time span.</p>","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":"30 1","pages":"10-12"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2003.02049.x","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Austriaca","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1046/j.1563-2571.2003.02049.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Summary: Purpose : Report on outcome of intraluminal high-dose-rate iridium-192 (HDR-Ir 192 ) brachytherapy with or without external radiotherapy in patients with unresectable bile duct tumours suffering from symptoms of malignant obstructive jaundice. Material and methods : Fourteen patients (mean age: 63 years) who were unsuitable for surgical resection on preoperative evaluation/laparotomy or inoperable due to poor general condition were referred for palliative radiotherapy. After percutaneous transhepatic drainage, HDR-Ir 192 brachytherapy was performed with a single dose of 2.5 Gy. Brachytherapy was given twice a day with at least a 6-h interval for 2 days, 2 or 3 days apart, up to a total dose of 10 Gy. Five patients received small-volume external radiotherapy (RT) (45 – 50.4 Gy/1.8 Gy) additionally. Results : Palliation with relief of the aggravating symptoms of obstructive jaundice was achieved in all patients. The actuarial 2-year survival rate of all patients was 11.9 % with a median survival of 6.5 months. Patients treated with brachytherapy alone had a median survival of 4.5 months as compared with 6.5 months after combined internal and external irradiation (log rank, P = 0.95). Conclusion : Patients with advanced unresectable bile duct cancer face a dismal prognosis; however, biliary drainage, and intraluminal brachytherapy with or without external RT, seem to be able to improve quality of life in the remaining time span.

不能切除的胆管肿瘤的姑息治疗
摘要:目的:报道腔内高剂量铱-192 (HDR-Ir -192)近距离放疗联合或不联合外放疗治疗伴有恶性梗阻性黄疸症状的不可切除胆管肿瘤患者的疗效。材料与方法:对术前评估不适合手术切除或一般情况不适合手术的14例患者(平均年龄63岁)进行姑息性放疗。经皮经肝引流后,采用单剂量2.5 Gy的HDR-Ir 192近距离治疗。近距离放射治疗每天两次,间隔至少6小时,间隔2天,间隔2或3天,总剂量为10 Gy。5例患者加行小体积外放疗(RT) (45 ~ 50.4 Gy/1.8 Gy)。结果:所有患者的梗阻性黄疸加重症状均得到缓解。所有患者的精算2年生存率为11.9%,中位生存期为6.5个月。单独接受近距离放疗的患者中位生存期为4.5个月,而内外照射联合治疗的患者中位生存期为6.5个月(log rank, P = 0.95)。结论:晚期不可切除胆管癌患者预后较差;然而,胆道引流和腔内近距离放射治疗,无论是否有外部放射治疗,似乎都能改善剩余时间内的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信